Elevated mid-regional pro-ANP (MR-proANP) plasma levels also predicted increased risk of major adverse CV events (MACE) and all-cause mortality in patients with type 2 diabetes mellitus, independently of CV risk factors and markers of subclinical organ damage [135]. The gene discussed is NPPA; the disease is type 2 diabetes mellitus.